期刊文献+

右美托咪定对小鼠成骨细胞RANKL/RANK/OPG信号通路的影响 被引量:2

The effect of dexmedetomidine on RANKL/RANK/OPG signaling pathway in mouse osteoblasts.
下载PDF
导出
摘要 目的观察比较不同浓度和时间条件下右美托咪定对小鼠成骨细胞RANKL/RANK/OPG信号通路的影响。方法将不同浓度右美托咪定加入小鼠成骨细胞培养液处理,共分为4组。对照组:含生理盐水的DMEM培养基;DEX1组:培养基中加入1μmol/L右美托咪定;DEX2组:用10μmol/L浓度右美托咪定处理细胞;DEX3组:用100μmol/L右美托咪定处理细胞。在16和24 h时点分别收集细胞,用Western blot法检测RANKL、OPG蛋白表达量及RANKL/OPG比值变化和条带宽度。结果 16 h时DEX3组、24 h时DEX1和DEX2组RANKL、OPG的表达均升高,与对照组比较差异均有统计学意义(P<0.05);而24 h时DEX3组的RANKL、OPG的表达与对照组比较差异无统计学意义(P>0.05)。16 h和24 h时点DEX1、DEX2、DEX3组RANKL/OPG比值与对照组比较差异均无统计学意义(P>0.05)。结论右美托咪定可能通过RANKL/RANK/OPG信号通路,引起小鼠成骨细胞RANKL、OPG表达变化,具体机制尚需进一步研究。 Objective To observe the effect of dexmedetomidine on RANKL/RANK/OPG signaling pathway in mouse osteoblasts. Methods The mouse osteoblasts were divided into four groups according to the concentration of dexmedetomidine, contrast group(DMEM medium contains physiological saline), DEX1 group(1 μmol/L dexmedetomidine), DEX2 group(10 μmol/L dexmedetomidine) and DEX3 group(100 μmol/L dexmedetomidine). The RANKL and OPG protein expression was measured and RANKL/OPG ratio was calculated. Results Compare with contrast group, RANKL and OPG expression were significantly elevated at the 16 hour in DEX3 group and at the 24 hour in DEX1 and DEX2 group. There was no significant difference in RANKL/OPG ratio between contrast group and experimental groups. Conclusion Dexmedetomidine may change RANKL and OPG expression through RANKL/RANK/OPG signaling pathway in mouse osteoblasts. However, the specific mechanism required further scientific research.
作者 蔡军 于刚 秦晗 CAI Jun;YU Gang;QIN Han(Department of anesthesiology, Maternal and Child Health hospital of Lianyungang city, Lianyungang 222006, China)
出处 《广东医学》 CAS 2019年第6期758-761,共4页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:81500893) 江苏省妇幼健康科研项目(编号:F201859)
关键词 右美托咪定 成骨细胞 RANKL/RANK/OPG信号通路 dexmedetomidine osteoblasts RANKL/RANK/OPG signaling pathway
  • 相关文献

参考文献5

二级参考文献29

  • 1张智海,沈建雄,刘忠厚.中国人骨质疏松症诊断标准回顾性研究[J].中国骨质疏松杂志,2004,10(3):255-262. 被引量:111
  • 2PEDRO M, MAGDALENA H, DIEGO F, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women[J]. Osteoporosis International, 2005,16(11): 1368- 1374.
  • 3ROGERS A, SALEH G, HANNON R A, et al. Circulating estradiol and osteoprotegerin as determinants of bone tumover and bone density in postmenopausal women[J]. J Clin Endocrind Metab, 2002, 87:4470-4475.
  • 4KHOSLA S, ARRIGHI H M, MELTON L J, et al. Correlates of osteoprotegerin levels in women and men [J]. Osteoporosis International,2002, 13: 394 - 399.
  • 5THOR U. GH/IGF- 1 and bone resorption in vivo and in vitro[J].European J Endocrinol, 2005, 152(3): 327- 332.
  • 6CORNY G, SHAW A, OURSLER M J. IL- 6 LIF, and TNF - alpha regulation of GM - CSF inhibition of osteoclastogenesis in vitro[J]. Experimental Cell Research, 2004, 294: 149- 158.
  • 7RUBIN J, ACKERT- BICKNELL C L, ZHU L, et al. IGF- 1 regulates osteoprotegerin (OPG) and receptor activator d nuclear factor -kappa B ligand in vitro and OPC in vivo[J]. Journal of Clinical Endocrinology and Metabolism, 2002, 87: 4273-4279.
  • 8UELAND T, BRIXEN K, MOSEKILDE L, et al. Age- related changes in cortical bone content d insulin - like growth factor binding protein (IGFBP) - 3, IGTBP - 5, osteoprotegerin, and calcium in postmenopausal osteoporoeis: a cross - sectional study[J]. Clinical Endoerinol and Metabolism, 2003, 88: 1014- 1018.
  • 9ASTRID F, HARALD D, CLAUDIA P, et al. Osteoprotegerin serum levels in women Correlation with age, bone mass [J]. Wien Klin Wochenschr, 2003, 115(9): 291-297.
  • 10GEORG S, STEFAN K, KURT R, et al. Soluble RANKL and Riskof Nontraumatic Fracture[J]. JAMA, 2004, 291(9): 1108 - 1113.

共引文献40

同被引文献16

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部